About Us
The Department of Genetic Medicine at Weill Cornell leads a dynamic and innovative translational research program, advancing diverse fields such as Genetic Therapy and Personalized Medicine.
In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine.
| Publication Type | Academic Article |
| Authors | Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowitz E, Crystal R, Weichselbaum R, Kufe D, Fine H |
| Journal | Hum Gene Ther |
| Volume | 7 |
| Issue | 6 |
| Pagination | 713-20 |
| Date Published | 04/10/1996 |
| ISSN | 1043-0342 |
| Keywords | Adenoviruses, Human, Defective Viruses, Flucytosine, Genetic Vectors, Gliosarcoma, Nucleoside Deaminases, Transduction, Genetic |
| Abstract | Viral vector-mediated transfer of chemosensitization genes represents a promising new approach to the treatment of cancer. Previous reports have demonstrated that transfection of the bacterial cytosine deaminase (cd) gene into mammalian cells can sensitize them to the otherwise nontoxic nucleoside, 5-fluorocytosine (5-FC). We now report that a replication-deficient adenovirus vector that transduces the cd gene (Ad.CMV-cd) highly sensitizes 9L gliosarcoma cells to 5-FC, and that gene transduction is associated with a potent bystander effect that is not dependent on direct cell-to-cell contact. Stereotactic injection of Ad.CMV-cd into established rat gliomas, followed by systemic administration of 5-FC in vivo, results in prolongation of survival. |
| DOI | 10.1089/hum.1996.7.6-713 |
| PubMed ID | 8919593 |